CN112439016A - 一种治疗急性软组织损伤的中药组合物、制备方法及应用 - Google Patents
一种治疗急性软组织损伤的中药组合物、制备方法及应用 Download PDFInfo
- Publication number
- CN112439016A CN112439016A CN201910821980.4A CN201910821980A CN112439016A CN 112439016 A CN112439016 A CN 112439016A CN 201910821980 A CN201910821980 A CN 201910821980A CN 112439016 A CN112439016 A CN 112439016A
- Authority
- CN
- China
- Prior art keywords
- parts
- frankincense
- dandelion
- mirabilite
- traditional chinese
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003814 drug Substances 0.000 title claims abstract description 73
- 239000000203 mixture Substances 0.000 title claims abstract description 32
- 208000026137 Soft tissue injury Diseases 0.000 title claims abstract description 28
- 230000001154 acute effect Effects 0.000 title claims abstract description 26
- 238000002360 preparation method Methods 0.000 title claims abstract description 17
- 239000004863 Frankincense Substances 0.000 claims abstract description 57
- 240000007551 Boswellia serrata Species 0.000 claims abstract description 47
- 235000003717 Boswellia sacra Nutrition 0.000 claims abstract description 45
- 235000012035 Boswellia serrata Nutrition 0.000 claims abstract description 45
- 241000218176 Corydalis Species 0.000 claims abstract description 40
- 241000334161 Cercis chinensis Species 0.000 claims abstract description 39
- 235000005187 Taraxacum officinale ssp. officinale Nutrition 0.000 claims abstract description 39
- 244000048199 Hibiscus mutabilis Species 0.000 claims abstract description 36
- 235000003973 Hibiscus mutabilis Nutrition 0.000 claims abstract description 36
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 claims abstract description 33
- 239000010446 mirabilite Substances 0.000 claims abstract description 32
- 241000779819 Syncarpia glomulifera Species 0.000 claims abstract description 29
- 239000001739 pinus spp. Substances 0.000 claims abstract description 29
- 229940036248 turpentine Drugs 0.000 claims abstract description 29
- 240000004980 Rheum officinale Species 0.000 claims abstract description 19
- 235000008081 Rheum officinale Nutrition 0.000 claims abstract description 19
- 229940079593 drug Drugs 0.000 claims abstract description 14
- 239000002994 raw material Substances 0.000 claims abstract description 10
- 239000000284 extract Substances 0.000 claims description 41
- 241000245665 Taraxacum Species 0.000 claims description 38
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 35
- 235000005206 Hibiscus Nutrition 0.000 claims description 33
- 235000007185 Hibiscus lunariifolius Nutrition 0.000 claims description 33
- 244000284380 Hibiscus rosa sinensis Species 0.000 claims description 33
- 239000000706 filtrate Substances 0.000 claims description 30
- 239000000843 powder Substances 0.000 claims description 26
- 239000000341 volatile oil Substances 0.000 claims description 25
- RSIJVJUOQBWMIM-UHFFFAOYSA-L sodium sulfate decahydrate Chemical compound O.O.O.O.O.O.O.O.O.O.[Na+].[Na+].[O-]S([O-])(=O)=O RSIJVJUOQBWMIM-UHFFFAOYSA-L 0.000 claims description 23
- 241000219061 Rheum Species 0.000 claims description 21
- 235000009411 Rheum rhabarbarum Nutrition 0.000 claims description 21
- 238000001914 filtration Methods 0.000 claims description 20
- 239000007788 liquid Substances 0.000 claims description 20
- 238000002156 mixing Methods 0.000 claims description 20
- 239000006071 cream Substances 0.000 claims description 19
- 241000717739 Boswellia sacra Species 0.000 claims description 12
- 239000002674 ointment Substances 0.000 claims description 6
- 238000010298 pulverizing process Methods 0.000 claims description 6
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 claims description 4
- NOPFSRXAKWQILS-UHFFFAOYSA-N docosan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCCCCCO NOPFSRXAKWQILS-UHFFFAOYSA-N 0.000 claims description 4
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 claims description 4
- 229940040145 liniment Drugs 0.000 claims description 3
- 239000000865 liniment Substances 0.000 claims description 3
- -1 liquid paraffin Substances 0.000 claims description 3
- 229940098465 tincture Drugs 0.000 claims description 3
- AXTGDCSMTYGJND-UHFFFAOYSA-N 1-dodecylazepan-2-one Chemical compound CCCCCCCCCCCCN1CCCCCC1=O AXTGDCSMTYGJND-UHFFFAOYSA-N 0.000 claims description 2
- NWGKJDSIEKMTRX-AAZCQSIUSA-N Sorbitan monooleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O NWGKJDSIEKMTRX-AAZCQSIUSA-N 0.000 claims description 2
- 235000021355 Stearic acid Nutrition 0.000 claims description 2
- 239000002775 capsule Substances 0.000 claims description 2
- 229960000541 cetyl alcohol Drugs 0.000 claims description 2
- 229960000735 docosanol Drugs 0.000 claims description 2
- 229940075507 glyceryl monostearate Drugs 0.000 claims description 2
- 239000008187 granular material Substances 0.000 claims description 2
- PYIDGJJWBIBVIA-UYTYNIKBSA-N lauryl glucoside Chemical compound CCCCCCCCCCCCO[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O PYIDGJJWBIBVIA-UYTYNIKBSA-N 0.000 claims description 2
- 229940057995 liquid paraffin Drugs 0.000 claims description 2
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 claims description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 claims description 2
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 claims description 2
- 239000006187 pill Substances 0.000 claims description 2
- 239000008117 stearic acid Substances 0.000 claims description 2
- 229960004274 stearic acid Drugs 0.000 claims description 2
- 239000003826 tablet Substances 0.000 claims description 2
- 239000003871 white petrolatum Substances 0.000 claims description 2
- 241000233948 Typha Species 0.000 claims 6
- 238000009472 formulation Methods 0.000 claims 3
- 239000003937 drug carrier Substances 0.000 claims 1
- 229940048848 lauryl glucoside Drugs 0.000 claims 1
- 235000019271 petrolatum Nutrition 0.000 claims 1
- 239000002966 varnish Substances 0.000 claims 1
- 240000001949 Taraxacum officinale Species 0.000 abstract 1
- 206010042674 Swelling Diseases 0.000 description 30
- 230000008961 swelling Effects 0.000 description 30
- 230000036407 pain Effects 0.000 description 26
- 208000002193 Pain Diseases 0.000 description 25
- 240000001398 Typha domingensis Species 0.000 description 24
- 239000008280 blood Substances 0.000 description 24
- 210000004369 blood Anatomy 0.000 description 24
- 230000000694 effects Effects 0.000 description 24
- 241000700159 Rattus Species 0.000 description 20
- 239000011159 matrix material Substances 0.000 description 16
- 208000014674 injury Diseases 0.000 description 15
- 238000000034 method Methods 0.000 description 9
- 208000027418 Wounds and injury Diseases 0.000 description 8
- 230000001737 promoting effect Effects 0.000 description 8
- 230000006378 damage Effects 0.000 description 7
- 238000004821 distillation Methods 0.000 description 7
- 210000004185 liver Anatomy 0.000 description 7
- 230000008736 traumatic injury Effects 0.000 description 7
- 206010007247 Carbuncle Diseases 0.000 description 6
- 206010061218 Inflammation Diseases 0.000 description 6
- 102000004889 Interleukin-6 Human genes 0.000 description 6
- 108090001005 Interleukin-6 Proteins 0.000 description 6
- 206010024453 Ligament sprain Diseases 0.000 description 6
- 229940100601 interleukin-6 Drugs 0.000 description 6
- 238000011160 research Methods 0.000 description 6
- 208000004998 Abdominal Pain Diseases 0.000 description 5
- 208000010040 Sprains and Strains Diseases 0.000 description 5
- 230000017531 blood circulation Effects 0.000 description 5
- 230000004054 inflammatory process Effects 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- 201000000736 Amenorrhea Diseases 0.000 description 4
- 206010001928 Amenorrhoea Diseases 0.000 description 4
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 4
- 231100000540 amenorrhea Toxicity 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 230000000144 pharmacologic effect Effects 0.000 description 4
- 206010002383 Angina Pectoris Diseases 0.000 description 3
- 206010051625 Conjunctival hyperaemia Diseases 0.000 description 3
- 208000005171 Dysmenorrhea Diseases 0.000 description 3
- 206010013935 Dysmenorrhoea Diseases 0.000 description 3
- 241000196324 Embryophyta Species 0.000 description 3
- 206010018852 Haematoma Diseases 0.000 description 3
- 206010023126 Jaundice Diseases 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 3
- 206010030113 Oedema Diseases 0.000 description 3
- 230000003110 anti-inflammatory effect Effects 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 238000001816 cooling Methods 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 230000000968 intestinal effect Effects 0.000 description 3
- 208000004396 mastitis Diseases 0.000 description 3
- 230000004089 microcirculation Effects 0.000 description 3
- 210000003205 muscle Anatomy 0.000 description 3
- 230000001717 pathogenic effect Effects 0.000 description 3
- 238000011552 rat model Methods 0.000 description 3
- 210000000952 spleen Anatomy 0.000 description 3
- 210000002784 stomach Anatomy 0.000 description 3
- 229920001864 tannin Polymers 0.000 description 3
- 235000018553 tannin Nutrition 0.000 description 3
- 239000001648 tannin Substances 0.000 description 3
- 235000019640 taste Nutrition 0.000 description 3
- 210000002435 tendon Anatomy 0.000 description 3
- 210000000115 thoracic cavity Anatomy 0.000 description 3
- 231100000331 toxic Toxicity 0.000 description 3
- 230000002588 toxic effect Effects 0.000 description 3
- 102000003390 tumor necrosis factor Human genes 0.000 description 3
- 210000002700 urine Anatomy 0.000 description 3
- 210000003462 vein Anatomy 0.000 description 3
- 239000008096 xylene Substances 0.000 description 3
- 235000018062 Boswellia Nutrition 0.000 description 2
- 206010010774 Constipation Diseases 0.000 description 2
- 229920000858 Cyclodextrin Polymers 0.000 description 2
- 239000001293 FEMA 3089 Substances 0.000 description 2
- 239000001116 FEMA 4028 Substances 0.000 description 2
- 206010017553 Furuncle Diseases 0.000 description 2
- 208000034507 Haematemesis Diseases 0.000 description 2
- 208000032843 Hemorrhage Diseases 0.000 description 2
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
- 206010061876 Obstruction Diseases 0.000 description 2
- 240000007711 Peperomia pellucida Species 0.000 description 2
- 208000004880 Polyuria Diseases 0.000 description 2
- 206010053615 Thermal burn Diseases 0.000 description 2
- 208000025865 Ulcer Diseases 0.000 description 2
- 206010000269 abscess Diseases 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- 150000001335 aliphatic alkanes Chemical class 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 description 2
- 235000011175 beta-cyclodextrine Nutrition 0.000 description 2
- 229960004853 betadex Drugs 0.000 description 2
- 230000000740 bleeding effect Effects 0.000 description 2
- 239000000679 carrageenan Substances 0.000 description 2
- 235000010418 carrageenan Nutrition 0.000 description 2
- 229920001525 carrageenan Polymers 0.000 description 2
- 229940113118 carrageenan Drugs 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 230000004087 circulation Effects 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 235000009508 confectionery Nutrition 0.000 description 2
- 230000002354 daily effect Effects 0.000 description 2
- 229960001193 diclofenac sodium Drugs 0.000 description 2
- 230000035619 diuresis Effects 0.000 description 2
- 239000003651 drinking water Substances 0.000 description 2
- 235000020188 drinking water Nutrition 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 208000001780 epistaxis Diseases 0.000 description 2
- 229930003935 flavonoid Natural products 0.000 description 2
- 150000002215 flavonoids Chemical class 0.000 description 2
- 235000017173 flavonoids Nutrition 0.000 description 2
- 210000002683 foot Anatomy 0.000 description 2
- 150000004676 glycans Chemical class 0.000 description 2
- 238000005469 granulation Methods 0.000 description 2
- 230000003179 granulation Effects 0.000 description 2
- 238000005286 illumination Methods 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 210000000281 joint capsule Anatomy 0.000 description 2
- 210000002429 large intestine Anatomy 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 231100000915 pathological change Toxicity 0.000 description 2
- 230000036285 pathological change Effects 0.000 description 2
- 210000003516 pericardium Anatomy 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 208000001297 phlebitis Diseases 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- JGMJQSFLQWGYMQ-UHFFFAOYSA-M sodium;2,6-dichloro-n-phenylaniline;acetate Chemical compound [Na+].CC([O-])=O.ClC1=CC=CC(Cl)=C1NC1=CC=CC=C1 JGMJQSFLQWGYMQ-UHFFFAOYSA-M 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 150000003505 terpenes Chemical class 0.000 description 2
- 235000007586 terpenes Nutrition 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 150000003648 triterpenes Chemical class 0.000 description 2
- 231100000397 ulcer Toxicity 0.000 description 2
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 2
- KZJWDPNRJALLNS-VPUBHVLGSA-N (-)-beta-Sitosterol Natural products O[C@@H]1CC=2[C@@](C)([C@@H]3[C@H]([C@H]4[C@@](C)([C@H]([C@H](CC[C@@H](C(C)C)CC)C)CC4)CC3)CC=2)CC1 KZJWDPNRJALLNS-VPUBHVLGSA-N 0.000 description 1
- CSVWWLUMXNHWSU-UHFFFAOYSA-N (22E)-(24xi)-24-ethyl-5alpha-cholest-22-en-3beta-ol Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(C)C=CC(CC)C(C)C)C1(C)CC2 CSVWWLUMXNHWSU-UHFFFAOYSA-N 0.000 description 1
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
- KLEXDBGYSOIREE-UHFFFAOYSA-N 24xi-n-propylcholesterol Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)CCC(CCC)C(C)C)C1(C)CC2 KLEXDBGYSOIREE-UHFFFAOYSA-N 0.000 description 1
- QCVGEOXPDFCNHA-UHFFFAOYSA-N 5,5-dimethyl-2,4-dioxo-1,3-oxazolidine-3-carboxamide Chemical compound CC1(C)OC(=O)N(C(N)=O)C1=O QCVGEOXPDFCNHA-UHFFFAOYSA-N 0.000 description 1
- GOZMBJCYMQQACI-UHFFFAOYSA-N 6,7-dimethyl-3-[[methyl-[2-[methyl-[[1-[3-(trifluoromethyl)phenyl]indol-3-yl]methyl]amino]ethyl]amino]methyl]chromen-4-one;dihydrochloride Chemical compound Cl.Cl.C=1OC2=CC(C)=C(C)C=C2C(=O)C=1CN(C)CCN(C)CC(C1=CC=CC=C11)=CN1C1=CC=CC(C(F)(F)F)=C1 GOZMBJCYMQQACI-UHFFFAOYSA-N 0.000 description 1
- 206010000077 Abdominal mass Diseases 0.000 description 1
- 206010000087 Abdominal pain upper Diseases 0.000 description 1
- 206010063409 Acarodermatitis Diseases 0.000 description 1
- 208000006820 Arthralgia Diseases 0.000 description 1
- 241000208838 Asteraceae Species 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 241000208229 Burseraceae Species 0.000 description 1
- 206010007882 Cellulitis Diseases 0.000 description 1
- 206010008479 Chest Pain Diseases 0.000 description 1
- LPZCCMIISIBREI-MTFRKTCUSA-N Citrostadienol Natural products CC=C(CC[C@@H](C)[C@H]1CC[C@H]2C3=CC[C@H]4[C@H](C)[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C)C(C)C LPZCCMIISIBREI-MTFRKTCUSA-N 0.000 description 1
- 206010010726 Conjunctival oedema Diseases 0.000 description 1
- 241000830532 Corydalis yanhusuo Species 0.000 description 1
- 241000721047 Danaus plexippus Species 0.000 description 1
- ARVGMISWLZPBCH-UHFFFAOYSA-N Dehydro-beta-sitosterol Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)CCC(CC)C(C)C)CCC33)C)C3=CC=C21 ARVGMISWLZPBCH-UHFFFAOYSA-N 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 206010014025 Ear swelling Diseases 0.000 description 1
- 102000002322 Egg Proteins Human genes 0.000 description 1
- 108010000912 Egg Proteins Proteins 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 206010015866 Extravasation Diseases 0.000 description 1
- 241000220485 Fabaceae Species 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 208000003098 Ganglion Cysts Diseases 0.000 description 1
- 208000000616 Hemoptysis Diseases 0.000 description 1
- GQODBWLKUWYOFX-UHFFFAOYSA-N Isorhamnetin Natural products C1=C(O)C(C)=CC(C2=C(C(=O)C3=C(O)C=C(O)C=C3O2)O)=C1 GQODBWLKUWYOFX-UHFFFAOYSA-N 0.000 description 1
- 208000032912 Local swelling Diseases 0.000 description 1
- 208000019255 Menstrual disease Diseases 0.000 description 1
- 206010027514 Metrorrhagia Diseases 0.000 description 1
- 208000007101 Muscle Cramp Diseases 0.000 description 1
- 208000000112 Myalgia Diseases 0.000 description 1
- 240000001307 Myosotis scorpioides Species 0.000 description 1
- 241000218180 Papaveraceae Species 0.000 description 1
- 208000006735 Periostitis Diseases 0.000 description 1
- 241000218641 Pinaceae Species 0.000 description 1
- 235000005205 Pinus Nutrition 0.000 description 1
- 241000218602 Pinus <genus> Species 0.000 description 1
- 235000011613 Pinus brutia Nutrition 0.000 description 1
- 241000219050 Polygonaceae Species 0.000 description 1
- 235000008090 Rheum palmatum Nutrition 0.000 description 1
- 240000001745 Rheum palmatum Species 0.000 description 1
- 241000447727 Scabies Species 0.000 description 1
- 229930182558 Sterol Natural products 0.000 description 1
- PJANXHGTPQOBST-VAWYXSNFSA-N Stilbene Natural products C=1C=CC=CC=1/C=C/C1=CC=CC=C1 PJANXHGTPQOBST-VAWYXSNFSA-N 0.000 description 1
- 208000005400 Synovial Cyst Diseases 0.000 description 1
- 241000292546 Taraxacum mongolicum Species 0.000 description 1
- 206010043189 Telangiectasia Diseases 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 208000002474 Tinea Diseases 0.000 description 1
- 241000130764 Tinea Species 0.000 description 1
- 206010053476 Traumatic haemorrhage Diseases 0.000 description 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
- 235000004224 Typha angustifolia Nutrition 0.000 description 1
- 208000019790 abdominal distention Diseases 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 208000038016 acute inflammation Diseases 0.000 description 1
- 230000006022 acute inflammation Effects 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 150000003797 alkaloid derivatives Chemical class 0.000 description 1
- PYKYMHQGRFAEBM-UHFFFAOYSA-N anthraquinone Natural products CCC(=O)c1c(O)c2C(=O)C3C(C=CC=C3O)C(=O)c2cc1CC(=O)OC PYKYMHQGRFAEBM-UHFFFAOYSA-N 0.000 description 1
- 150000004056 anthraquinones Chemical class 0.000 description 1
- RJGDLRCDCYRQOQ-UHFFFAOYSA-N anthrone Chemical compound C1=CC=C2C(=O)C3=CC=CC=C3CC2=C1 RJGDLRCDCYRQOQ-UHFFFAOYSA-N 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 229940124599 anti-inflammatory drug Drugs 0.000 description 1
- 230000006793 arrhythmia Effects 0.000 description 1
- 206010003119 arrhythmia Diseases 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 229940107666 astragalus root Drugs 0.000 description 1
- 235000019606 astringent taste Nutrition 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- ZYGHJZDHTFUPRJ-UHFFFAOYSA-N benzo-alpha-pyrone Natural products C1=CC=C2OC(=O)C=CC2=C1 ZYGHJZDHTFUPRJ-UHFFFAOYSA-N 0.000 description 1
- MJVXAPPOFPTTCA-UHFFFAOYSA-N beta-Sistosterol Natural products CCC(CCC(C)C1CCC2C3CC=C4C(C)C(O)CCC4(C)C3CCC12C)C(C)C MJVXAPPOFPTTCA-UHFFFAOYSA-N 0.000 description 1
- LGJMUZUPVCAVPU-UHFFFAOYSA-N beta-Sitostanol Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(C)CCC(CC)C(C)C)C1(C)CC2 LGJMUZUPVCAVPU-UHFFFAOYSA-N 0.000 description 1
- NJKOMDUNNDKEAI-UHFFFAOYSA-N beta-sitosterol Natural products CCC(CCC(C)C1CCC2(C)C3CC=C4CC(O)CCC4C3CCC12C)C(C)C NJKOMDUNNDKEAI-UHFFFAOYSA-N 0.000 description 1
- 230000002146 bilateral effect Effects 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 230000001914 calming effect Effects 0.000 description 1
- 230000004856 capillary permeability Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 210000000038 chest Anatomy 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 235000001671 coumarin Nutrition 0.000 description 1
- 150000004775 coumarins Chemical class 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 230000002951 depilatory effect Effects 0.000 description 1
- 230000000916 dilatatory effect Effects 0.000 description 1
- 230000003467 diminishing effect Effects 0.000 description 1
- 229930004069 diterpene Natural products 0.000 description 1
- 150000004141 diterpene derivatives Chemical class 0.000 description 1
- 229940000406 drug candidate Drugs 0.000 description 1
- 208000001848 dysentery Diseases 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 235000014103 egg white Nutrition 0.000 description 1
- 210000000969 egg white Anatomy 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 239000003777 experimental drug Substances 0.000 description 1
- 230000036251 extravasation Effects 0.000 description 1
- 210000003414 extremity Anatomy 0.000 description 1
- 210000003195 fascia Anatomy 0.000 description 1
- 239000010685 fatty oil Substances 0.000 description 1
- 229930182486 flavonoid glycoside Natural products 0.000 description 1
- 150000007955 flavonoid glycosides Chemical class 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 229940075000 frankincense extract Drugs 0.000 description 1
- 239000013505 freshwater Substances 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 208000014617 hemorrhoid Diseases 0.000 description 1
- 229960001340 histamine Drugs 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 235000008800 isorhamnetin Nutrition 0.000 description 1
- 239000008141 laxative Substances 0.000 description 1
- 210000002414 leg Anatomy 0.000 description 1
- 210000003041 ligament Anatomy 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 201000003453 lung abscess Diseases 0.000 description 1
- 201000007227 lymph node tuberculosis Diseases 0.000 description 1
- 230000001926 lymphatic effect Effects 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 230000002175 menstrual effect Effects 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- 208000013465 muscle pain Diseases 0.000 description 1
- 208000004296 neuralgia Diseases 0.000 description 1
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 1
- 239000008601 oleoresin Substances 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 206010033675 panniculitis Diseases 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- 210000003460 periosteum Anatomy 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 150000007965 phenolic acids Chemical class 0.000 description 1
- 235000009048 phenolic acids Nutrition 0.000 description 1
- 150000002989 phenols Chemical class 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 229940068065 phytosterols Drugs 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000004417 polycarbonate Substances 0.000 description 1
- 229920000515 polycarbonate Polymers 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000002947 procoagulating effect Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000001543 purgative effect Effects 0.000 description 1
- 238000010926 purge Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000002040 relaxant effect Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 208000005687 scabies Diseases 0.000 description 1
- 229930009674 sesquiterpene lactone Natural products 0.000 description 1
- 150000002107 sesquiterpene lactone derivatives Chemical class 0.000 description 1
- KZJWDPNRJALLNS-VJSFXXLFSA-N sitosterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CC[C@@H](CC)C(C)C)[C@@]1(C)CC2 KZJWDPNRJALLNS-VJSFXXLFSA-N 0.000 description 1
- 235000015500 sitosterol Nutrition 0.000 description 1
- 229950005143 sitosterol Drugs 0.000 description 1
- NLQLSVXGSXCXFE-UHFFFAOYSA-N sitosterol Natural products CC=C(/CCC(C)C1CC2C3=CCC4C(C)C(O)CCC4(C)C3CCC2(C)C1)C(C)C NLQLSVXGSXCXFE-UHFFFAOYSA-N 0.000 description 1
- 230000037380 skin damage Effects 0.000 description 1
- 230000008470 skin growth Effects 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 229910052979 sodium sulfide Inorganic materials 0.000 description 1
- GRVFOGOEDUUMBP-UHFFFAOYSA-N sodium sulfide (anhydrous) Chemical compound [Na+].[Na+].[S-2] GRVFOGOEDUUMBP-UHFFFAOYSA-N 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 150000003432 sterols Chemical class 0.000 description 1
- 235000003702 sterols Nutrition 0.000 description 1
- PJANXHGTPQOBST-UHFFFAOYSA-N stilbene Chemical compound C=1C=CC=CC=1C=CC1=CC=CC=C1 PJANXHGTPQOBST-UHFFFAOYSA-N 0.000 description 1
- 235000021286 stilbenes Nutrition 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 210000004304 subcutaneous tissue Anatomy 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 229910052600 sulfate mineral Inorganic materials 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 208000009056 telangiectasis Diseases 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 230000000472 traumatic effect Effects 0.000 description 1
- 210000000689 upper leg Anatomy 0.000 description 1
- 230000002227 vasoactive effect Effects 0.000 description 1
- 238000009423 ventilation Methods 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/04—Sulfur, selenium or tellurium; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/13—Coniferophyta (gymnosperms)
- A61K36/15—Pinaceae (Pine family), e.g. pine or cedar
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/288—Taraxacum (dandelion)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/32—Burseraceae (Frankincense family)
- A61K36/324—Boswellia, e.g. frankincense
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/66—Papaveraceae (Poppy family), e.g. bloodroot
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/70—Polygonaceae (Buckwheat family), e.g. spineflower or dock
- A61K36/708—Rheum (rhubarb)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation or decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Biotechnology (AREA)
- Mycology (AREA)
- Alternative & Traditional Medicine (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physical Education & Sports Medicine (AREA)
- Inorganic Chemistry (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
本发明涉及一种中药组合物、制备方法及其应用,该中药组合物由如下重量份的原料药制成:芒硝1‑10份、大黄2‑30份、蒲黄1‑10份、延胡索1‑10份、蒲公英1‑20份、乳香1‑10份、紫荆皮1‑20份、木芙蓉叶1‑20份、松节油1‑10份,其可用于治疗急性软组织损伤。
Description
技术领域
本发明属于医药领域,具体涉及一种治疗急性软组织损伤的中药组合物、制备方法及其应用。
背景技术
软组织损伤是一种常见的非特异性疾病。包括急性损伤(Acute trauma)和慢性损伤(Chronic strain)。急性软组织损伤是指机体皮下组织、筋膜、肌肉、肌腱韧带、滑膜囊、骨膜、关节囊、脂肪组织等部位直接或间接地受到各种外来暴力导致相应的病理变化,临床以局部肿胀、瘀血青紫、疼痛、肢体活动功能障碍为主要表现。
急性软组织损伤属于中医学“伤筋”范畴,主要原因为跌打、扭扑等外力损伤,引起脉络受损、气机运行阻滞、血不归经、溢出脉外所致,主要病机为“气滞与血瘀并见”,即气滞血瘀、脉络不和。《医宗金鉴》云:“损伤之症,肿痛者,乃瘀血凝结作痛也。”说明急性软组织损伤之肿痛主要是因瘀血凝结所致。治疗主要以消肿止痛、疏通筋络、活血化瘀等为主。
现代医学认为急性软组织损伤是由于损伤局部释放血管活性物质和组胺等炎性介质,使损伤部位发生一系列的微循环变化,其主要治疗方法是消炎、局部封闭止痛等。消炎基本采用的都是非甾体消炎药,长期服用会有一定的毒副作用,局部封闭更是治标不治本,对急性软组织损伤的治疗疗效欠佳,康复时间较长。
中医治疗软组织损伤有着悠久的历史,形成了综合治疗体系,长期的医疗实践证实疗效显著。其中尤以中药外治法独具特色,包括患处敷药、腾洗药清洗、擦剂、酊剂涂于患处等。软组织损伤部位通过透皮吸收外用中药中所含的某些生物活性物质,并维持损伤局部相对稳定的血药浓度,以达到活血祛瘀、镇痛消肿的功效,效果显著。
发明内容
本发明的目的在于提供一种消热消肿、化瘀止痛,用于治疗急性软组织损伤的中药组合物。具体由如下中药原料药制备而成:芒硝、大黄、蒲黄、延胡索、蒲公英、乳香、紫荆皮、木芙蓉叶和松节油。
优选的,本发明所述中药组合物由如下重量份的原料药制成:芒硝1-10份、大黄2-30份、蒲黄1-10份、延胡索1-10份、蒲公英1-20份、乳香1-10份、紫荆皮1-20份、木芙蓉叶1-20份、松节油1-10份。
优选地,由如下重量份的原料药制成:芒硝2-8份、大黄5-20份、蒲黄2-8份、延胡索2-5份、蒲公英2-10份、乳香1-5份、紫荆皮2-10份、木芙蓉叶2-10份、松节油1-5份。
更优选地,由如下重量份的原料药制成:
芒硝5份、大黄10份、蒲黄5份、延胡索3份、蒲公英5份、乳香2份、紫荆皮5份、木芙蓉叶5份、松节油1份。
芒硝7份、大黄9份、蒲黄3份、延胡索2份、蒲公英6份、乳香3份、紫荆皮4份、木芙蓉叶6份、松节油1份。
芒硝6份、大黄10份、蒲黄6份、延胡索3份、蒲公英4份、乳香3份、紫荆皮3份、木芙蓉叶4份、松节油2份。
其中,所述乳香为制乳香。
本发明采用大黄清热凉血、祛瘀,为君药;芒硝清火消肿,蒲黄止血,化瘀共为臣药;蒲公英佐大黄清热解毒,延胡索佐大黄逐瘀通经,乳香活血行气止痛,紫荆皮活血解毒,芙蓉叶清热解毒、凉血止血、消肿止痛,共为佐药。松节油活血通络,消肿止痛,为使药。
以下是本发明中药组合物原料药的性味及功能:
大黄
大黄为蓼科植物掌叶大黄Rheum palmatum L.的干燥根和根茎。
性味苦,寒。归脾、胃、大肠、肝、心包经。功能泻下攻积,清热泻火,凉血解毒,逐瘀通经,利湿退黄。用于实热积滞便秘,血热吐衄,目赤咽肿,痈肿疔疮,肠痈腹痛,瘀血经闭,产后瘀阻,跌打损伤,湿热痢疾,黄疸尿赤,淋证,水肿;外治烧烫伤。大黄的主要化学成分为蒽醌类、蒽酮类、二苯乙烯类、鞣质、有机酸及多糖类等。
在大黄外用药理研究中发现,不同品种大黄油糊剂均能显著减轻二甲苯导致耳廓肿胀;显著抑制大鼠蛋清性足跖肿胀;使溃疡面积显著减小,加快溃疡愈合,明显改善受损组织病理变化;提示大黄具有抗炎、减轻局部炎症、改善皮肤受损,促进创面肉芽及皮肤生长的作用。
芒硝
芒硝为硫酸盐类矿物芒硝族芒硝,经加工精制而成的结晶体。
性味咸、苦,寒。归胃、大肠经。功能泻下通便,润燥软坚,清火消肿。用于实热积滞,腹满胀痛,大便燥结,肠痈肿痛;外治乳痈,痔疮肿痛。主含含水硫酸钠(Na2SO4·10H2O)。
现代药理研究证实,芒硝能够加快淋巴循环、减轻肿胀。刘绍龑等观察芒硝外用对小鼠皮肤毛细血管通透性及家兔耳静脉炎的影响,发现芒硝溶液外用对急性炎症有好的抑制作用,对兔耳静脉炎有好的治疗作用。
蒲黄
蒲黄为香蒲科植物水烛香蒲Typha angustifolia L.的干燥花粉。
性味甘,平。归肝、心包经。功能止血,化瘀,通淋。用于吐血,衄血,咯血,崩漏,外伤出血,经闭痛经,胸腹刺痛,跌扑肿痛,血淋涩痛。蒲黄的主要含有黄酮类,甾醇类,烷烃类,有机酸类,多糖类以及鞣质等化学成分。
蒲黄内含有异鼠李素的苷、谷甾醇、烷类、酸类、挥发油、氨基酸、脂肪油及多种糖,可起到促凝血作用;另又有扩血管、改善微循环作用。朱智超对外伤性体表血肿患者在伤后48h内采用蒲黄外敷法治疗,血肿能较快地被吸收消退,疗效显著。
蒲公英
蒲公英为菊科植物蒲公英Taraxacum mongolicum Hand.-Mazz.的干燥全草。
性味苦、甘,寒。归肝、胃经。功能清热解毒,消肿散结,利尿通淋。用于疔疮肿毒,乳痈,瘰疬,目赤,咽痛,肺痈,肠痈,湿热黄疸,热淋涩痛。蒲公英的活性成分主要有黄酮类、萜类、酚酸类、蒲公英色素、植物甾醇类、倍半萜内酯类和香豆素类等。
蒲公英有广谱抑菌作用,大量研究表明蒲公英在体外对革兰阳性球菌、革兰阴性球菌、真菌等均有明显抑制作用,且不易产生耐药。蒲公英还具有很强的抗炎作用,其可有效抑制体内毛细血管扩张和通透性亢进、渗出水肿、纤维组织增生,具有明显的体内抗炎活性。临床研究文献表明,蒲公英外敷可以治疗湿疹、腱鞘囊肿、会阴水肿、肌肉中硬结、乳痈初起、体表血肿、蜂窝组织炎等疾病,并见良效。
延胡索
延胡索,又称元胡,为罂粟科植物延胡索Corydalis yanhusuo W.T.Wang的干燥块茎。
性味辛、苦,温。归肝、脾经。功能活血,行气,止痛。用于胸胁、脘腹疼痛,胸痹心痛,经闭痛经,产后瘀阻,跌扑肿痛。延胡索主要的药效学物质是延胡索生物碱。
现代实验表明延胡索有很好的镇痛、抗血栓、改善微循环、治疗心绞痛和抗心率失常作用。
乳香
乳香为橄榄科植物乳香树Boswellia carterii Birdw.树皮渗出的树脂。
性味辛、苦,温。归心、肝、脾经。功能活血定痛,消肿生肌。用于胸痹心痛,胃脘疼痛,痛经经闭,产后瘀阻,癥瘕腹痛,风湿痹痛,筋脉拘挛,跌打损伤,痈肿疮疡。乳香主要含有五环三萜、四环三萜、大环二萜等萜类和多种挥发油类成分。
研究表明乳香水提液具有良好的抗炎作用。对乳香提取物临床前的研究发现,其能减轻膝关节炎患者的疼痛,增强骨关节的屈伸以减少关节部位的隆突并有修复功能。
紫荆皮
紫荆皮为豆科植物紫荆Cercis chinensis Bunge的干燥树皮。
性味苦,平。归肝经。功能活血通淋,解毒消肿。用于月经不调,瘀滞腹痛,小便淋痛,痈肿,疥癣,跌打损伤。
现代药理学研究表明,紫荆皮具有抗炎、镇痛、抑菌、镇静等作用。临床有用紫荆皮等药物组成的方剂外敷治疗运动性损伤疾病及急性踝关节扭伤的记录。
木芙蓉叶(芙蓉叶)
木芙蓉叶为锦葵科植物木芙蓉Hibiscus mutabilis L.的干燥叶。
性味辛,平;归肺、肝经。功能凉血,解毒,消肿,止痛。治痈疽焮肿,缠身蛇丹,烫伤,目赤肿痛,跌打损伤。木芙蓉叶含黄酮甙、酚类、氨基酸、鞣质、还原糖等成分。
通过二甲苯致小鼠耳肿胀的影响试验,表明木芙蓉叶具有明显抑制二甲苯造成的耳非特异性肿胀作用。林浩然等也通过实验发现木芙蓉叶水煎剂对角叉菜碱致大鼠足肿胀有明显抑制作用,切除大鼠双侧肾上腺后木芙蓉水煎剂对角叉菜碱所致大鼠足肿胀仍有显著抑制作用,说明木芙蓉叶有明确抗非特异性炎症作用。
松节油
松节油为松科松属数种植物中渗出的油树脂,经蒸馏或其他方法提取的挥发油。
松节油对皮肤有较强的刺激作用,还有一定的消毒作用,主要用作外用刺激剂。用于减轻肌肉痛、关节痛、神经痛以及扭伤。
本发明目的还在于提供所述中药组合物的制备方法,具体制备方法如下:
方案一:大黄、蒲黄、延胡索、蒲公英、乳香(制)、紫荆皮、芙蓉叶,加6-12倍量水,煎煮1-3次,每次1-2小时,煎液滤过,合并滤液,减压浓缩至相对密度为1.15~1.20(60℃)的浸膏,备用;芒硝粉碎成细粉,备用;将浸膏、细粉和松节油混合,即得。
方案二:乳香(制)加6-10倍量水,蒸馏提取挥发油3-8小时,得乳香挥发油和乳香药液,备用;大黄、蒲黄、、延胡索、蒲公英、紫荆皮、芙蓉叶,加6-12倍量水,煎煮1-3次,每次1-2小时,煎液滤过,合并滤液,与乳香药液合并减压浓缩至相对密度为1.15~1.20(60℃)的浸膏,备用;芒硝粉碎成细粉,备用;将浸膏、细粉、乳香挥发油和松节油混合,即得。
其中,所述蒲黄为包煎。
本发明的又一目的在于提供本发明所述中药组合物的制剂,其由有效量的上述中药组合物及可接受的药用载体制备而成。该制剂可以是软膏剂、颗粒剂、丸剂、胶囊剂、片剂、搽剂、涂剂、涂膜剂、酊剂、贴剂和贴膏剂。。
优选的,所述中药组合物的制剂为软膏剂,更优选为乳膏剂。
所述乳膏剂由有效量的中药组合物及适量基质制备而成。
其中,所述基质为可用于软膏剂辅料的一种或多种的混合物,具体为硬脂酸、十六醇、单硬脂酸甘油酯、二十二烷基醇、十二烷基葡萄糖苷、液体石蜡、白凡士林、司盘-80、氮酮中的一种或多种。
本发明的目的还在于提供所述中药组合物在消热消肿、化瘀止痛,尤其是制备治疗急性软组织损伤药物中的应用。
与现有技术相比,本发明技术方案具有如下有益效果:
1、本发明中药组合物是结合中医理论及现代中药药理研究而得,以消热消肿,化瘀止痛为主,可用于急性扭伤、软组织损伤等,为临床用药提供了更多选择。
2、采用本发明所述中药组合物可明显改善急性扭伤、软组织损伤的症状,除消肿、化瘀止痛外,消热作用明显,对软组织损伤造成的疼痛、肿胀、红热等方面,疗效显著。
3、采用本发明的中药组合物制成乳膏剂,不仅疗效显著,而且疗程短,使用便利,刺激性小,经临床使用验证疗效确切、无明显的毒副反应。
4、本发明的中药组合物配方科学严谨,制备方法简单,制备成本低,具有很大的临床应用价值。
具体实施方式
下面将结合实施例对本发明的实施方案进行详细描述,但本领域技术人员将会理解,下列实施例仅用于说明本发明,而不应视为限定本发明的范围。实施例中的实验方法,如无特殊说明,均为常规方法;所用的药材原料、试剂材料等,如无特殊说明,均为市售购买产品。
实施例1
取大黄100g、蒲黄(包煎)50g、延胡索30g、蒲公英50g、乳香(制)20g、紫荆皮50g和木芙蓉叶50g,加10倍量水,煎煮2次,每次1小时,煎液滤过,合并滤液,减压浓缩至相对密度为1.25~1.30(60℃)的浸膏,备用;松节油10g备用;芒硝50g粉碎,备用;将上述浸膏、松节油、芒硝细粉以及适量基质混匀,制得乳膏。
实施例2
取乳香(制)30g加8倍量水,蒸馏提取挥发油4小时,挥发油、药液备用。取大黄90g、蒲黄(包煎)30g、延胡索20g、蒲公英60g、紫荆皮40g和木芙蓉叶60g,加10倍量水,煎煮2次,每次1小时,煎液滤过,合并滤液,与乳香药液合并减压浓缩至相对密度为1.15~1.20(60℃)的浸膏;松节油10g备用;芒硝70g粉碎,备用;将上述浸膏、松节油、芒硝细粉以及适量基质混匀,制得乳膏。
实施例3
取大黄100g、蒲黄(包煎)60g、延胡索30g、蒲公英40g、乳香(制)30g、紫荆皮30g和木芙蓉叶40g,加8倍量水,煎煮2次,每次2小时,煎液滤过,合并滤液,减压浓缩至相对密度为1.25~1.30(60℃)的浸膏,备用;松节油20g备用;芒硝60g粉碎,备用;将上述浸膏、松节油、芒硝细粉以及适量基质混匀,制得乳膏。
实施例4
取乳香(制)30g加10倍量水,蒸馏提取挥发油3小时,挥发油、药液备用。取大黄70g、蒲黄(包煎)80g、延胡索50g、蒲公英100g、紫荆皮20g和木芙蓉叶20g,加12倍量水,煎煮2次,每次1小时,煎液滤过,合并滤液,与乳香药液合并减压浓缩至相对密度为1.15~1.20(60℃)的浸膏;松节油10g备用;芒硝30g粉碎,备用;将上述浸膏、松节油、芒硝细粉以及适量基质混匀,制得乳膏。
实施例5
取大黄150g、蒲黄(包煎)30g、延胡索200g、蒲公英60g、乳香(制)10g、紫荆皮60g和木芙蓉叶60g,加6倍量水,煎煮3次,每次1小时,煎液滤过,合并滤液,减压浓缩至相对密度为1.25~1.30(60℃)的浸膏,备用;松节油20g备用;芒硝20g粉碎,备用;将上述浸膏、松节油、芒硝细粉以及适量基质混匀,制得乳膏。
实施例6
取乳香(制)40g加6倍量水,蒸馏提取挥发油8小时,挥发油、药液备用。取大黄120g、蒲黄(包煎)20g、延胡索30g、蒲公英80g、紫荆皮60g和木芙蓉叶20g,加6倍量水,煎煮3次,每次2小时,煎液滤过,合并滤液,与乳香药液合并减压浓缩至相对密度为1.15~1.20(60℃)的浸膏;松节油20g备用;芒硝50g粉碎,备用;将上述浸膏、松节油、芒硝细粉以及适量基质混匀,制得乳膏。
实施例7
取大黄180g、蒲黄(包煎)20g、延胡索30g、蒲公英20g、乳香(制)50g、紫荆皮30g和木芙蓉叶30g,加10倍量水,煎煮2次,每次1小时,煎液滤过,合并滤液,减压浓缩至相对密度为1.25~1.30(60℃)的浸膏,备用;松节油10g备用;芒硝80g粉碎,备用;将上述浸膏、松节油、芒硝细粉以及适量基质混匀,制得乳膏。
实施例8
取乳香(制)50g加10倍量水,蒸馏提取挥发油3小时,挥发油、药液备用。取大黄200g、蒲黄(包煎)20g、延胡索30g、蒲公英20g、紫荆皮30g和木芙蓉叶80g,加12倍量水,煎煮1次,每次2小时,煎液滤过,合并滤液,与乳香药液合并减压浓缩至相对密度为1.15~1.20(60℃)的浸膏;松节油20g备用;芒硝30g粉碎,备用;将上述浸膏、松节油、芒硝细粉以及适量基质混匀,制得乳膏。
实施例9
取大黄250g、蒲黄(包煎)10g、延胡索20g、蒲公英20g、乳香(制)50g、紫荆皮10g和木芙蓉叶30g,加9倍量水,煎煮2次,每次2小时,煎液滤过,合并滤液,减压浓缩至相对密度为1.25~1.30(60℃)的浸膏,备用;松节油30g备用;芒硝50g粉碎,备用;将上述浸膏、松节油、芒硝细粉以及适量基质混匀,制得乳膏。
实施例10
取乳香(制)80g加8倍量水,蒸馏提取挥发油4小时,挥发油、药液备用。取大黄200g、蒲黄(包煎)10g、延胡索20g、蒲公英20g、紫荆皮10g和木芙蓉叶30g,加10倍量水,煎煮2次,每次1小时,煎液滤过,合并滤液,与乳香药液合并减压浓缩至相对密度为1.15~1.20(60℃)的浸膏;松节油50g备用;芒硝20g粉碎,备用;将上述浸膏、松节油、芒硝细粉以及适量基质混匀,制得乳膏。
实施例11
取大黄30g、蒲黄(包煎)10g、延胡索100g、蒲公英60g、乳香(制)20g、紫荆皮150g和木芙蓉叶10g,加6倍量水,煎煮3次,每次2小时,煎液滤过,合并滤液,减压浓缩至相对密度为1.25~1.30(60℃)的浸膏,备用;松节油30g备用;芒硝50g粉碎,备用;将上述浸膏、松节油、芒硝细粉以及适量基质混匀,制得乳膏。
实施例12
取乳香(制)20g加10倍量水,蒸馏提取挥发油5小时,挥发油、药液备用。取大黄100g、蒲黄(包煎)10g、延胡索60g、蒲公英180g、紫荆皮30g和木芙蓉叶10g,加8倍量水,煎煮2次,每次2小时,煎液滤过,合并滤液,与乳香药液合并减压浓缩至相对密度为1.15~1.20(60℃)的浸膏;松节油30g备用;芒硝30g粉碎,备用;将上述浸膏、松节油、芒硝细粉以及适量基质混匀,制得乳膏。
实施例13
取大黄30g、蒲黄(包煎)10g、延胡索50g、蒲公英20g、乳香(制)20g、紫荆皮200g和木芙蓉叶10g,加10倍量水,煎煮2次,每次1小时,煎液滤过,合并滤液,减压浓缩至相对密度为1.25~1.30(60℃)的浸膏,备用;松节油30g备用;芒硝80g粉碎,备用;将上述浸膏、松节油、芒硝细粉以及适量基质混匀,制得乳膏。
实施例14
取乳香(制)30g加8倍量水,蒸馏提取挥发油4小时,挥发油、药液备用。取大黄280g、蒲黄(包煎)20g、延胡索20g、蒲公英20g、紫荆皮30g和木芙蓉叶30g,加10倍量水,煎煮2次,每次1小时,煎液滤过,合并滤液,与乳香药液合并减压浓缩至相对密度为1.15~1.20(60℃)的浸膏;松节油30g备用;芒硝20g粉碎,备用;将上述浸膏、松节油、芒硝细粉以及适量基质混匀,制得乳膏。
实施例15
取大黄50g、蒲黄(包煎)60g、延胡索20g、蒲公英20g、乳香(制)30g、紫荆皮50g和木芙蓉叶150g,加8倍量水,煎煮2次,每次2小时,煎液滤过,合并滤液,减压浓缩至相对密度为1.25~1.30(60℃)的浸膏,备用;松节油30g备用;芒硝20g粉碎,备用;将上述浸膏、松节油和芒硝细粉,用β-环糊精包合,干燥,粉碎,备用。以上细粉混合均匀,干法制粒,即得。
实施例16
取乳香(制)30g加6倍量水,蒸馏提取挥发油8小时,挥发油、药液备用。取大黄280g、蒲黄(包煎)20g、延胡索20g、蒲公英20g、紫荆皮30g和木芙蓉叶30g,加10倍量水,煎煮2次,每次1小时,煎液滤过,合并滤液,与乳香药液合并减压浓缩至相对密度为1.15~1.20(60℃)的浸膏;松节油30g备用;芒硝20g粉碎,备用;将上述浸膏、松节油和芒硝细粉,用β-环糊精包合,干燥,粉碎,备用。以上细粉混合均匀,干法制粒,即得。
药效试验例:本发明中药组合物对大鼠急性软组织损伤模型的治疗作用
实验目的
采用局部打击法建立急性软组织损伤的大鼠模型观察不同实施例乳膏对大鼠急性软组织损伤模型组织内白介素-6(IL-6)与肿瘤坏死因子(TNF-α)含量的影响。
实验药物与仪器
1.1药物
阳性对照药物:双氯芬酸钠凝胶(先声药业有限公司出品)、青鹏软膏(西藏林芝奇正藏药厂出品);
实验药物:本发明实施例组(折算后大鼠每天给药剂量2.88g生药/kg)。
1.2仪器与试剂
1.2.1仪器
百分之一电子天平:TP-1102,北京赛多利斯仪器系统有限公司;十万分之一分析天平:BP121S,Sartorius(赛多利斯);Nikon荧光显微镜(上海培清科技有限公司);TDZ5-WS多管架自动平衡离心机;
1.2.2试剂
1.3实验动物
SD大鼠:体重180~220g,雌性大鼠,SPF级(Specific Pathogen Free,无特定病原体),购自斯贝福(北京)生物技术有限公司;许可证编号:SCXK(京)2018-0011。
动物房:实验设施许可证:SYXK(京)2017-0026;设施管理遵循中华人民共和国国家标准GB14925-2001《实验动物环境及设施》
喂养条件:采用人工光照12小时明暗周期,环境温度维持在19~29℃,湿度在40%~80%,照明时间8:00~17:00,有通风系统保持室内空气流畅;动物饲养于聚碳酸酯小鼠饲养笼,每星期定时更换2次垫料,每天早晨定时换水和添加饲料。
饲料:标准大鼠颗粒饲料,由斯贝福(北京)生物技术有限公司公司提供。饮用水:试验动物饮用水,动物可自由摄取,每日更换新的水瓶和新鲜水。
2、试验方法
将大鼠按数字随机表法分为14组:空白对照组、模型对照组、双氯芬酸钠凝胶组、青鹏软膏组、本发明实施例组。造模前24小时用8%硫化钠脱毛剂脱去大鼠后腿大腿部鼠毛,除空白组大鼠外,其余大鼠均采用局部打击法建立急性软组织损伤的大鼠模型。造模后1小时各组给予相应处理,每日换药1次,各组疗程1周,大鼠给药量为5g乳膏或凝胶/kg。取材及标本制备分别于末次给药1h后,处死大鼠,取大鼠受打击部位中心的肌肉组织1g,10mg组织中注入0.5mL生理盐水,于匀浆器中缓慢而均匀地研磨至匀浆液呈均匀一致悬浊液时,离心,收集上清液,置于-20℃冰箱中备用。使用白介素-6(IL-6)与肿瘤坏死因子(TNF-α)试剂盒进行测定,结果如下:
表1本发明药物组合物对大鼠急性软组织损伤白介素-6(IL-6)和肿瘤坏死因子(TNF-α)的影响
与空白组相比:#P<0.05;##P<0.01;与模型组相比:*P<0.05;**P<0.01
从表中可以看出,本发明药物组合物均对急性软组织损伤大鼠炎性因子升高具有调节作用。可用于治疗急性扭伤、软组织损伤等。且观察大鼠受打击部位皮肤表面,有较为明显的消肿、化瘀作用。
Claims (10)
1.一种治疗急性软组织损伤的中药组合物,其特征在于,由如下重量份的原料药制成:芒硝1-10份、大黄2-30份、蒲黄1-10份、延胡索1-10份、蒲公英1-20份、乳香1-10份、紫荆皮1-20份、木芙蓉叶1-20份、松节油1-10份。
2.根据权利要求1所述的中药组合物,其特征在于,由如下重量份的原料药制成:芒硝2-8份、大黄5-20份、蒲黄2-8份、延胡索2-5份、蒲公英2-10份、乳香1-5份、紫荆皮2-10份、木芙蓉叶2-10份、松节油1-5份。
3.根据权利要求1所述的中药组合物,其特征在于,由如下重量份的原料药制成:芒硝5份、大黄10份、蒲黄5份、延胡索3份、蒲公英5份、乳香2份、紫荆皮5份、木芙蓉叶5份、松节油1份;
芒硝7份、大黄9份、蒲黄3份、延胡索2份、蒲公英6份、乳香3份、紫荆皮4份、木芙蓉叶6份、松节油1份;
芒硝6份、大黄10份、蒲黄6份、延胡索3份、蒲公英4份、乳香3份、紫荆皮3份、木芙蓉叶4份、松节油2份。
4.根据权利要求1-3任一所述的中药组合物,其特征在于,所述乳香为制乳香。
5.根据权利要求1-3任一所述中药组合物的制备方法,其特征在于,具体步骤如下:
方案一:大黄、蒲黄、延胡索、蒲公英、乳香、紫荆皮、芙蓉叶,加6-12倍量水,煎煮1-3次,每次1-2小时,煎液滤过,合并滤液,减压浓缩至相对密度为1.15~1.20(60℃)的浸膏,备用;芒硝粉碎成细粉,备用;将浸膏、细粉和松节油混合,即得;
方案二:乳香加6-10倍量水,蒸馏提取挥发油3-8小时,得乳香挥发油和乳香药液,备用;大黄、蒲黄、延胡索、蒲公英、紫荆皮、芙蓉叶,加6-12倍量水,煎煮1-3次,每次1-2小时,煎液滤过,合并滤液,与乳香药液合并减压浓缩至相对密度为1.15~1.20(60℃)的浸膏,备用;芒硝粉碎成细粉,备用;将浸膏、细粉、乳香挥发油及松节油混合,即得;
优选的,所述蒲黄为包煎。
6.根据权利要求1-3任一所述中药组合物的制剂,其特征在于,由有效量的中药组合物及可接受的药用载体制备而成。
7.根据权利要求6所述的制剂,其特征在于,所述制剂为软膏剂、颗粒剂、丸剂、胶囊剂、片剂、搽剂、涂剂、涂膜剂、酊剂、贴剂或贴膏剂。
8.根据权利要求7所述的制剂,其特征在于,所述软膏剂为乳膏剂,其由有效量的中药组合物及适量基质制备而成。
9.根据权利要求8所述的制剂,其特征在于,所述基质可为硬脂酸、十六醇、单硬脂酸甘油酯、二十二烷基醇、十二烷基葡萄糖苷、液体石蜡、白凡士林、司盘-80、氮酮中的一种或多种。
10.根据权利要求1-3任一所述中药组合物在制备治疗急性软组织损伤药物中的应用。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201910821980.4A CN112439016B (zh) | 2019-09-02 | 2019-09-02 | 一种治疗急性软组织损伤的中药组合物、制备方法及应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201910821980.4A CN112439016B (zh) | 2019-09-02 | 2019-09-02 | 一种治疗急性软组织损伤的中药组合物、制备方法及应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN112439016A true CN112439016A (zh) | 2021-03-05 |
CN112439016B CN112439016B (zh) | 2023-07-25 |
Family
ID=74733895
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201910821980.4A Active CN112439016B (zh) | 2019-09-02 | 2019-09-02 | 一种治疗急性软组织损伤的中药组合物、制备方法及应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN112439016B (zh) |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102302565A (zh) * | 2011-09-15 | 2012-01-04 | 上海交通大学医学院附属新华医院 | 一种用于软组织损伤和颈椎病的消瘀散 |
CN105125794A (zh) * | 2015-09-06 | 2015-12-09 | 青岛大学 | 一种治疗急性运动闭合性损伤的纯中药乳膏及其制备方法 |
-
2019
- 2019-09-02 CN CN201910821980.4A patent/CN112439016B/zh active Active
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102302565A (zh) * | 2011-09-15 | 2012-01-04 | 上海交通大学医学院附属新华医院 | 一种用于软组织损伤和颈椎病的消瘀散 |
CN105125794A (zh) * | 2015-09-06 | 2015-12-09 | 青岛大学 | 一种治疗急性运动闭合性损伤的纯中药乳膏及其制备方法 |
Non-Patent Citations (1)
Title |
---|
金立伦;: "消瘀散治疗急性软组织损伤的临床疗效" * |
Also Published As
Publication number | Publication date |
---|---|
CN112439016B (zh) | 2023-07-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102091203B (zh) | 一种治疗难愈性创面的外用中药制剂及其制备方法 | |
CN1883618B (zh) | 一种祖师麻有效部位及其制备方法与应用 | |
CN102058673B (zh) | 一种祛风除湿的中药组合物及其制备方法 | |
CN102178804A (zh) | 一种治疗肛周湿疹的中药组合物及其制备方法 | |
CN101284107B (zh) | 一种治癌药物及其制备方法 | |
CN102626477B (zh) | 治疗陈年跌打损伤外用中草药组合物 | |
CN105477126A (zh) | 一种用于治疗抑郁症的中药提取物组合物及其制备方法和应用 | |
CN107007784B (zh) | 用于逆转Aβ淀粉样蛋白损伤神经细胞的中药组合物及其制备方法与应用 | |
CN112439016B (zh) | 一种治疗急性软组织损伤的中药组合物、制备方法及应用 | |
CN1883679A (zh) | 一种治疗肺结核的药物 | |
CN110384785B (zh) | 一种用于治疗病毒性感冒的外用中药药液及其制备方法 | |
CN106421283A (zh) | 一种治疗皮肤疾病的中药药膏 | |
CN111991527A (zh) | 足药浴配方及其制备工艺 | |
CN101940652B (zh) | 治疗牛皮癣、各种顽癣、瘙痒症的中药擦剂 | |
CN103989969A (zh) | 用于治疗风寒痹阻型神经根型颈椎病的中药及其制备方法 | |
CN112402565B (zh) | 一种治疗膝关节滑膜炎的中药组合物及其制备方法 | |
CN112402566B (zh) | 一种中药组合物在制备治疗膝关节滑膜炎的药物中的用途 | |
CN111084842B (zh) | 治疗肩周炎、颈椎病、腰椎间盘突出、骨性关节炎的外用中药组合物 | |
CN114470063B (zh) | 一种用于治疗软组织损伤的复方中药片 | |
CN118593632B (zh) | 一种祛风除湿消炎止痛的中药组合物及其制备方法和应用 | |
CN108143965A (zh) | 一种辅助针灸治疗风湿的中药 | |
CN105770538A (zh) | 一种治疗血液透析患者血管通路局部硬结的中药 | |
CN105497817A (zh) | 一种用于踝关节外伤后肿胀的中药制剂及其制备方法 | |
CN105232886A (zh) | 三龙跌打酒及制备方法 | |
CN105362944A (zh) | 一种治疗骨科扭挫伤的中药膏剂 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 40053908 Country of ref document: HK |
|
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
REG | Reference to a national code |
Ref country code: HK Ref legal event code: WD Ref document number: 40053908 Country of ref document: HK |